NYBC Ventures

NYBC Ventures is an investment fund dedicated to accelerating breakthroughs in blood and cellular therapies and their supporting technologies. It strategically invests in early to mid-stage innovations across hematology, transfusion medicine, cell therapy, and infectious disease, seeking to advance therapeutics, devices, and other solutions. The fund distinguishes itself by leveraging the extensive expertise of New York Blood Center.

The fund was founded in 2021 by Dr. Christopher D. Hillyer, who serves as a General Partner and Manager. Launched by New York Blood Center Enterprises (NYBCe) with a significant commitment, Dr. Hillyer’s vision stemmed from his background as President and CEO of NYBCe and an internationally recognized expert in hematology, transfusion, and cellular/gene therapies. His insight was to create a dedicated investment vehicle to translate foundational research and clinical knowledge from NYBCe into impactful commercial innovations.

NYBC Ventures supports promising companies that are developing solutions to address critical challenges in its focus areas. Its long-term vision is to drive innovation in blood-related fields and cellular therapies, ultimately improving patient lives globally. The fund aims to be a catalyst for companies striving to bring forward new medical advancements.